Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
A coalition of 34 scientific and medical organizations led by the American Association of Immunologists and the American College of Physicians released the following statement.
The Protecting Pharmacies in Medicaid Act would prohibit the use of spread pricing arrangements in Medicaid programs. Pharmacy benefit managers (PBMs) would be required to pass through to pharmacies the full amount of the money paid to the PBMs by Medicaid programs, except for a fixed administrative fee. The total reimbursement amount will be determined by a survey of national average drug acquisition costs administered by the Department of Health & Human Services.
Over the weekend, Congressional leadership released a continuing resolution (CR) that extends government funding at the same level as the previous fiscal year, through September 30. Congress must extend government funding by March 14 to avoid a government shutdown.
In AMCP's latest comments to the FDA, we emphasize the need for standardized public reporting of confirmatory trial progress, ensuring payers and health care providers have the necessary data to make informed coverage decisions. By supporting proactive communication and rigorous confirmatory trials, AMCP aims to balance early access to innovative treatments with patient safety and long-term therapeutic value.
On Feb. 26, the House Energy & Commerce Health Subcommittee held a hearing titled: "An Examination of How Reining in PBMs Will Drive Competition and Lower Costs for Patients.“
Academy of Managed Care Pharmacy (AMCP) issued the following statement from AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, about the confirmation of Robert F. Kennedy Jr. as Secretary of the Department of Health and Human Services (HHS).
Immediately following the 2024 presidential election, GOP leaders in the House of Representatives, Senate, and incoming administration expressed a desire to use a procedural tool to advance partisan spending legislation.
View AMCP comments to the CMS’s Advance Notice of Methodological Changes for Calendar Year (CY) 2026 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies
View AMCP comments to the CMS’s Draft CY 2026 Part D Redesign Program Instructions.
Academy of Managed Care Pharmacy (AMCP) issued the following statement from AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, about President Trump’s potential executive order to cut thousands of jobs at the Department of Health and Human Services:
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics” (Draft Guidance), issued on December 5, 2024.
